vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and LOGITECH INTERNATIONAL S.A. (LOGI). Click either name above to swap in a different company.
LOGITECH INTERNATIONAL S.A. is the larger business by last-quarter revenue ($1.4B vs $1.2B, roughly 1.2× Jazz Pharmaceuticals plc). LOGITECH INTERNATIONAL S.A. runs the higher net margin — 17.7% vs 17.0%, a 0.7% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 6.1%). LOGITECH INTERNATIONAL S.A. produced more free cash flow last quarter ($465.6M vs $345.8M). Over the past eight quarters, LOGITECH INTERNATIONAL S.A.'s revenue compounded faster (18.5% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Logitech International S.A. is a Swiss multinational manufacturer of computer peripherals and software. Headquartered in Lausanne, Switzerland, the company has offices throughout Europe, Asia, Oceania, and the Americas. It is a component of the Swiss Market Index, and is listed on the Nasdaq.
JAZZ vs LOGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.4B |
| Net Profit | $203.5M | $251.0M |
| Gross Margin | — | 43.2% |
| Operating Margin | 21.2% | 20.1% |
| Net Margin | 17.0% | 17.7% |
| Revenue YoY | 10.1% | 6.1% |
| Net Profit YoY | 6.5% | 25.4% |
| EPS (diluted) | $3.34 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $897.8M | $1.0B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $902.0M | $1.0B |
| Q4 25 | $203.5M | $251.0M | ||
| Q3 25 | $251.4M | $170.7M | ||
| Q2 25 | $-718.5M | $146.0M | ||
| Q1 25 | $-92.5M | $144.1M | ||
| Q4 24 | $191.1M | $200.1M | ||
| Q3 24 | $215.1M | $145.5M | ||
| Q2 24 | $168.6M | $141.8M | ||
| Q1 24 | $-14.6M | $167.6M |
| Q4 25 | — | 43.2% | ||
| Q3 25 | — | 43.4% | ||
| Q2 25 | — | 41.7% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 42.8% | ||
| Q1 24 | — | 43.2% |
| Q4 25 | 21.2% | 20.1% | ||
| Q3 25 | 5.1% | 16.1% | ||
| Q2 25 | -65.6% | 14.1% | ||
| Q1 25 | -6.2% | 10.5% | ||
| Q4 24 | 17.5% | 17.5% | ||
| Q3 24 | 24.7% | 14.4% | ||
| Q2 24 | 19.5% | 14.1% | ||
| Q1 24 | 7.3% | 12.9% |
| Q4 25 | 17.0% | 17.7% | ||
| Q3 25 | 22.3% | 14.4% | ||
| Q2 25 | -68.7% | 12.7% | ||
| Q1 25 | -10.3% | 14.3% | ||
| Q4 24 | 17.6% | 14.9% | ||
| Q3 24 | 20.4% | 13.0% | ||
| Q2 24 | 16.5% | 13.0% | ||
| Q1 24 | -1.6% | 16.6% |
| Q4 25 | $3.34 | $1.69 | ||
| Q3 25 | $4.08 | $1.15 | ||
| Q2 25 | $-11.74 | $0.98 | ||
| Q1 25 | $-1.52 | $0.94 | ||
| Q4 24 | $2.97 | $1.32 | ||
| Q3 24 | $3.42 | $0.95 | ||
| Q2 24 | $2.49 | $0.92 | ||
| Q1 24 | $-0.23 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $1.8B |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $2.3B |
| Total Assets | $11.7B | $4.1B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.9B | $1.5B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.2B | $1.4B | ||
| Q2 24 | $1.4B | $1.5B | ||
| Q1 24 | $1.4B | $1.5B |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $2.3B | ||
| Q3 25 | $4.0B | $2.1B | ||
| Q2 25 | $3.7B | $2.2B | ||
| Q1 25 | $4.2B | $2.1B | ||
| Q4 24 | $4.1B | $2.1B | ||
| Q3 24 | $4.2B | $2.1B | ||
| Q2 24 | $3.8B | $2.2B | ||
| Q1 24 | $3.7B | $2.2B |
| Q4 25 | $11.7B | $4.1B | ||
| Q3 25 | $11.4B | $3.7B | ||
| Q2 25 | $10.9B | $3.7B | ||
| Q1 25 | $11.5B | $3.5B | ||
| Q4 24 | $12.0B | $3.7B | ||
| Q3 24 | $12.3B | $3.6B | ||
| Q2 24 | $11.4B | $3.7B | ||
| Q1 24 | $11.3B | $3.6B |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $480.5M |
| Free Cash FlowOCF − Capex | $345.8M | $465.6M |
| FCF MarginFCF / Revenue | 28.9% | 32.8% |
| Capex IntensityCapex / Revenue | 1.4% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.78× | 1.91× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $903.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $480.5M | ||
| Q3 25 | $474.6M | $228.8M | ||
| Q2 25 | $88.9M | $125.0M | ||
| Q1 25 | $429.8M | $129.7M | ||
| Q4 24 | $398.6M | $370.9M | ||
| Q3 24 | $398.7M | $166.0M | ||
| Q2 24 | $331.4M | $176.0M | ||
| Q1 24 | $267.2M | $239.1M |
| Q4 25 | $345.8M | $465.6M | ||
| Q3 25 | $459.4M | $212.3M | ||
| Q2 25 | $75.9M | $108.8M | ||
| Q1 25 | $415.9M | $116.9M | ||
| Q4 24 | $385.3M | $356.6M | ||
| Q3 24 | $388.0M | $151.5M | ||
| Q2 24 | $324.3M | $161.4M | ||
| Q1 24 | $260.3M | $228.8M |
| Q4 25 | 28.9% | 32.8% | ||
| Q3 25 | 40.8% | 17.9% | ||
| Q2 25 | 7.3% | 9.5% | ||
| Q1 25 | 46.3% | 11.6% | ||
| Q4 24 | 35.4% | 26.6% | ||
| Q3 24 | 36.8% | 13.6% | ||
| Q2 24 | 31.7% | 14.8% | ||
| Q1 24 | 28.9% | 22.6% |
| Q4 25 | 1.4% | 1.0% | ||
| Q3 25 | 1.3% | 1.4% | ||
| Q2 25 | 1.2% | 1.4% | ||
| Q1 25 | 1.5% | 1.3% | ||
| Q4 24 | 1.2% | 1.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 0.7% | 1.3% | ||
| Q1 24 | 0.8% | 1.0% |
| Q4 25 | 1.78× | 1.91× | ||
| Q3 25 | 1.89× | 1.34× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | 2.09× | 1.85× | ||
| Q3 24 | 1.85× | 1.14× | ||
| Q2 24 | 1.97× | 1.24× | ||
| Q1 24 | — | 1.43× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
LOGI
| Retail Gaming | $482.7M | 34% |
| Retail Keyboards Desktops | $254.6M | 18% |
| Retail Pointing Devices | $241.2M | 17% |
| Retail Video Collaboration | $193.3M | 14% |
| Retail Tablet And Other Accessories | $93.6M | 7% |
| Retail Webcams | $82.3M | 6% |
| Retail Headsets | $45.9M | 3% |
| Other Retail Products | $28.0M | 2% |
